Erin McDonnell1, David Schoenfeld2, Sabrina Paganoni2, Nazem Atassi2. 1. From the Biostatistics Center (E.M., D.S.) and Neurological Clinical Research Institute (S.P., N.A.), Massachusetts General Hospital; and Harvard Medical School (D.S., S.P., N.A.), Boston, MA. EIM726@mail.harvard.edu NAtassi@mgh.harvard.edu. 2. From the Biostatistics Center (E.M., D.S.) and Neurological Clinical Research Institute (S.P., N.A.), Massachusetts General Hospital; and Harvard Medical School (D.S., S.P., N.A.), Boston, MA.
Abstract
OBJECTIVE: To estimate effects of gastric tube (G-tube) on survival and quality of life (QOL) in people with amyotrophic lateral sclerosis (ALS) correcting for confounding by indication inherent in nonrandomized observational data. METHODS: To complement a recent causal inference analysis, which concluded that G-tube placement increases the hazard of death, permanent assisted ventilation, or tracheostomy by 28%, we fit causal inference models on a different sample of 481 patients with ALS enrolled in a recent clinical trial of ceftriaxone. Forward selection identified predictors of G-tube placement. Effects of G-tube on survival and QOL were estimated using structural nested models and marginal structural models, accounting for predictors of G-tube treatment. RESULTS: Forced vital capacity and the total score and bulbar subscale of the revised ALS Functional Rating Scale best predicted G-tube placement. Correcting for these confounders, G-tube placement decreased survival time by 46% (p < 0.001) and had no effect on QOL (p = 0.078). Sensitivity survival analyses varied in significance, but none revealed a survival benefit. CONCLUSIONS: In the absence of randomization, causal inference methods are necessary to correct for time-varying confounding. G-tube placement may have a negative effect on survival with no QOL-related benefit for people with ALS. A randomized controlled trial is warranted to further evaluate the efficacy of this widely used intervention. CLINICALTRIALSGOV IDENTIFIER: NCT00349622. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with ALS, G-tube placement decreases survival time and does not affect QOL.
OBJECTIVE: To estimate effects of gastric tube (G-tube) on survival and quality of life (QOL) in people with amyotrophic lateral sclerosis (ALS) correcting for confounding by indication inherent in nonrandomized observational data. METHODS: To complement a recent causal inference analysis, which concluded that G-tube placement increases the hazard of death, permanent assisted ventilation, or tracheostomy by 28%, we fit causal inference models on a different sample of 481 patients with ALS enrolled in a recent clinical trial of ceftriaxone. Forward selection identified predictors of G-tube placement. Effects of G-tube on survival and QOL were estimated using structural nested models and marginal structural models, accounting for predictors of G-tube treatment. RESULTS: Forced vital capacity and the total score and bulbar subscale of the revised ALS Functional Rating Scale best predicted G-tube placement. Correcting for these confounders, G-tube placement decreased survival time by 46% (p < 0.001) and had no effect on QOL (p = 0.078). Sensitivity survival analyses varied in significance, but none revealed a survival benefit. CONCLUSIONS: In the absence of randomization, causal inference methods are necessary to correct for time-varying confounding. G-tube placement may have a negative effect on survival with no QOL-related benefit for people with ALS. A randomized controlled trial is warranted to further evaluate the efficacy of this widely used intervention. CLINICALTRIALSGOV IDENTIFIER: NCT00349622. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with ALS, G-tube placement decreases survival time and does not affect QOL.
Authors: Kristen Zamietra; Erik B Lehman; Stephanie H Felgoise; Susan M Walsh; Helen E Stephens; Zachary Simmons Journal: Amyotroph Lateral Scler Date: 2012-01
Authors: Miguel A Hernán; Stephen R Cole; Joseph Margolick; Mardge Cohen; James M Robins Journal: Pharmacoepidemiol Drug Saf Date: 2005-07 Impact factor: 2.890
Authors: Merit E Cudkowicz; Sarah Titus; Marianne Kearney; Hong Yu; Alexander Sherman; David Schoenfeld; Douglas Hayden; Amy Shui; Benjamin Brooks; Robin Conwit; Donna Felsenstein; David J Greenblatt; Myles Keroack; John T Kissel; Robert Miller; Jeffrey Rosenfeld; Jeffrey D Rothstein; Ericka Simpson; Nina Tolkoff-Rubin; Lorne Zinman; Jeremy M Shefner Journal: Lancet Neurol Date: 2014-10-05 Impact factor: 44.182
Authors: Z Simmons; S H Felgoise; B A Bremer; S M Walsh; D J Hufford; M B Bromberg; W David; D A Forshew; T D Heiman-Patterson; E C Lai; L McCluskey Journal: Neurology Date: 2006-11-14 Impact factor: 9.910
Authors: Anne-Marie Wills; Jane Hubbard; Eric A Macklin; Jonathan Glass; Rup Tandan; Ericka P Simpson; Benjamin Brooks; Deborah Gelinas; Hiroshi Mitsumoto; Tahseen Mozaffar; Gregory P Hanes; Shafeeq S Ladha; Terry Heiman-Patterson; Jonathan Katz; Jau-Shin Lou; Katy Mahoney; Daniela Grasso; Robert Lawson; Hong Yu; Merit Cudkowicz Journal: Lancet Date: 2014-02-28 Impact factor: 79.321
Authors: R G Miller; C E Jackson; E J Kasarskis; J D England; D Forshew; W Johnston; S Kalra; J S Katz; H Mitsumoto; J Rosenfeld; C Shoesmith; M J Strong; S C Woolley Journal: Neurology Date: 2009-10-13 Impact factor: 9.910
Authors: James D Berry; Jeremy M Shefner; Robin Conwit; David Schoenfeld; Myles Keroack; Donna Felsenstein; Lisa Krivickas; William S David; Francine Vriesendorp; Alan Pestronk; James B Caress; Jonathan Katz; Ericka Simpson; Jeffrey Rosenfeld; Robert Pascuzzi; Jonathan Glass; Kourosh Rezania; Jeffrey D Rothstein; David J Greenblatt; Merit E Cudkowicz Journal: PLoS One Date: 2013-04-17 Impact factor: 3.240